Hepatitis c virus direct-acting antiviral drug interactions and use in renal and hepatic impairment

Topics in Antiviral Medicine

Volumn 23, Issue 2, 2015, Pages 92-96

  Hill, Lucas ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

DAAs; Direct acting antiviral drugs; Drug exposure; Drug drug interactions; HCV; Hepatic impairment; Hepatitis C virus; Renal impairment

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; ANTIMYCOBACTERIAL AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; ANXIOLYTIC AGENT; ASUNAPREVIR; CALCIUM CHANNEL BLOCKING AGENT; CISAPRIDE; COBICISTAT; CYTOCHROME P450 3A; DACLATASVIR; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; DEXAMETHASONE; DIGOXIN; ERYTHROMYCIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPERICUM PERFORATUM EXTRACT; LEDIPASVIR; MACROLIDE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR PLUS TIPRANAVIR; SILYBUM MARIANUM EXTRACT; SIMEPREVIR; SOFOSBUVIR; TIPRANAVIR; UNINDEXED DRUG;

ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; DRUG EXPOSURE; DRUG METABOLISM; DRUG SAFETY; HEPATITIS C; HUMAN; KIDNEY DISEASE; LIVER DISEASE; MAXIMUM PLASMA CONCENTRATION; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); COMPLICATION; DRUG INTERACTION; HEPATITIS C, CHRONIC; KIDNEY FAILURE; LIVER FAILURE;

ANTIVIRAL AGENTS; DRUG INTERACTIONS; HEPATITIS C, CHRONIC; HUMANS; LIVER FAILURE; RENAL INSUFFICIENCY;

EID: 84953728200     PISSN: 21615861     EISSN: 21615853     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Ouwerkerk Mahadevan S, Simion S, Spittaels K, Beumont-Mauviel M. Pharmacokinetics of simeprevir (TMC435) in volunteers with moderate or severe hepatic impairment. 48th Annual Meeting of the European Association for the Study of the Liver (EASL). April 24-28, 2013; Amsterdam, The Netherlands.
2. Cornpropst M, Denning J, demons D, et al. The effect of renal impairment and end-stage renal disease on the single-dose pharmacokinetics of GS-7977. 47th Annual Meeting of the European Association for the Study of the Liver (EASL). April 18-22, 2012; Barcelona, Spain.
3. Menon RM, Badri P, Das U, et al. Drug-drug ineractions with direct-acting antiviral combination therapy of ABT-450/r, ombitasvir, and dasabuvir [Abstract A-007]. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September 5-9, 2014; Washington, DC.
4. Kwo P, Mantry P, Coakley E, et al. Results of the phase 2 study Ml2-999: interfer-on-free regimen of ABT-450/r/ABT-267 + ABT-333 + ribavirin in liver transplant recipients with recurrent HCV genotype 1 infection [Abstract OH4]. 49th Annual Meeting of the European Association for the Study of the Liver (EASL). April 9-13, 2014; London, United Kingdom.
5. Khatri A, Gaultier IA, Menon R, et al. Pharmacokinetics and safety of coadministered ABT-450 plus ritonavir (ABT 450/r), ABT-267, and ABT-333 as a single dose in subjects with normal hepatic function and in subjects with mild, moderate, and severe hepatic impairment. 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). November 9-12, 2012; Boston, Massachusetts.
6. Bifano M, Adamczyk R, Hwang C, et al. Daclatasvir pharmacokinetics in healthy subjects: no clinically relevant drug-drug interaction with either cyclosporine or tacrolimus. 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). November 1-5, 2013; Washington, DC.
7. Bifano M, Hwang C, Oosterhuis B, et al. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretro-viral agents: ritonavir-boosted atazanavir, efavirenz, and tenofovir. Antivir Ther. 2013;18(7):931-940.
8. Garimella T, Wang R, Luo W-L, et al. The effect of renal impairment on single-dose pharmacokinetics of daclatasvir, an HCV NS5A inhibitor. 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy. May 19-21, 2014; Washington, DC.
9. Bifano M, Sevinsky H, Persson A, et al. Single-dose pharmacokinetics of daclatasvir (DCV; BMS-790052) in subjects with hepatic impairment compared with healthy subjects. 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). November 6-9, 2011; San Francisco, California.
10. Eley T, He B, Chang I, et al. The effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitor. Antivir Ther. 2014;[Epub ahead of print].
11. Garimella T, He B, Luo W-L, et al. Asunaprevir pharmacokinetics and safety in subjects with impaired renal function. 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). November 1-5, 2013; Washington, DC.
12. Eley T, He B, Huang S, et al. Effect of multiple-dose ketoconazole and the effect of multiple-dose rifampin on pharmacokinetics (PK) of the HCV NS3 protease inhibitor asunaprevir. 8th International Workshop on Clinical Pharmacology of Hepatitis Therapy. June 26-27, 2013; Cambridge, Massachusetts.
13. Kiser JJ, Burton JR, Jr, Everson GT Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol 2013;10(10):596-606.